

SB0265S01 compared with SB0265

~~{deleted text}~~ shows text that was in SB0265 but was deleted in SB0265S01.

inserted text shows text that was not in SB0265 but was inserted into SB0265S01.

DISCLAIMER: This document is provided to assist you in your comparison of the two bills. Sometimes this automated comparison will NOT be completely accurate. Therefore, you need to read the actual bills. This automatically generated document could contain inaccuracies caused by: limitations of the compare program; bad input data; or other causes.

~~{INSURANCE COVERAGE FOR}~~ Senator Jerry W. Stevenson proposes the following substitute bill:

ABUSE DETERRENT OPIOID~~{~~ ~~}~~ ANALGESIC DRUG PRODUCTS

2015 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Jerry W. Stevenson

House Sponsor: _____

LONG TITLE

General Description:

This bill enacts language related to ~~{a health benefit plan that covers an}~~ the study of abuse-deterrent opioid analgesic drug ~~{product}~~ products.

Highlighted Provisions:

This bill:

- ▶ defines terms; and
- ▶ requires ~~{a health benefit plan that covers an opioid analgesic drug product to cover abuse-deterrent}~~ the Public Employees' Benefit and Insurance Program to:
 - study the barriers to and efficacy of use of abuse-deterrent opioid analgesic drug

SB0265S01 compared with SB0265

products ~~{ and meet other certain requirements }~~; and

- report to the Business and Labor Interim Committee and the Health and Human Services Interim Committee.

Money Appropriated in this Bill:

None

Other Special Clauses:

None

Utah Code Sections Affected:

ENACTS:

~~{31A-22-644}~~ 49-20-412, Utah Code Annotated 1953

63I-2-249, Utah Code Annotated 1953

Be it enacted by the Legislature of the state of Utah:

Section 1. Section ~~{31A-22-644}~~ 49-20-412 is enacted to read:

~~{31A-22-644}~~ 49-20-412. ~~{ Insurance coverage for }~~ Study of abuse-deterrent opioid analgesic drug products.

(1) As used in this section:

(a) "Abuse-deterrent opioid analgesic drug product" means an opioid analgesic drug product with labeling approved by the {United States } Food and Drug Administration {that indicates} indicating that the product has properties that are expected to reduce abuse of the product.

~~{ (b) "Cost-sharing" means any coverage limit, copayment, coinsurance, deductible, or similar out-of-pocket expense incurred by an insured under a policy or certificate of health insurance.~~

~~(c) (i) "Health benefit plan" means a contract for health insurance described in Section 31A-22-600.~~

~~(ii) "Health benefit plan" includes a plan offered under Chapter 8, Health Maintenance Organizations and Limited Health Plans.~~

~~(d) "Lowest cost-sharing level" means the cost-sharing requirements applied to a drug product for which an insured incurs the least amount of out-of-pocket expenses.~~

~~{ (c) b }~~ "Opioid analgesic drug product" means a { drug } product in the opioid analgesic

SB0265S01 compared with SB0265

drug class that is prescribed to treat moderate to severe pain, regardless of whether the drug is combined with other substances in a single product or dosage form.

~~(2) {A health benefit plan that provides coverage of opioid analgesic drug products shall provide coverage}~~For purposes of the report required by Subsection (3), the program shall study available information regarding the barriers to and the efficacy of the use of
abuse-deterrent opioid analgesic drug products.

~~(3) {A health benefit plan may not impose:~~

~~—— (a) cost-sharing requirements on the coverage of abuse-deterrent opioid analgesic drug products that exceed the lowest cost-sharing level for any other prescription drug covered by the plan; or~~

~~—— (b) prior authorization requirements or other utilization control measures to require initial treatment using an opioid analgesic drug product without abuse-deterrent properties before an insured may be prescribed or dispensed an abuse-deterrent opioid analgesic drug product.~~

~~—— (4) A health benefit plan may impose on an abuse-deterrent opioid analgesic drug product prior authorization requirements or other utilization control measures only if the same requirements or measures are applied to another opioid analgesic drug product without abuse-deterrent properties.~~

~~(5) An insurer may not:~~

~~—— (a) increase the lowest cost-sharing level imposed on drugs covered by the plan in order to comply with this section; or~~

~~—— (b) create a financial disincentive for a prescriber or dispenser to prescribe or dispense an abuse-deterrent opioid analgesic drug product.~~

Legislative Review Note

~~—— as of 2-24-15 12:03 PM~~

~~Office of Legislative Research and General Counsel}~~The program shall report to the

SB0265S01 compared with SB0265

Business and Labor Interim Committee and the Health and Human Services Committee by no later than the respective committee's November 2015 interim committee regarding the study required by Subsection (2).

Section 2. Section **63I-2-249** is enacted to read:

63I-2-249. Repeal dates -- Title 49.

Section 49-20-412 is repealed January 1, 2016.